Mainz Biomed B.V. Logo

Mainz Biomed B.V.

Ins Portfolio
- 0,00
Gettex Realtime-Kurs vom 30.03.2023 (heute) in Euro, 19:44 Uhr


Für dieses Unternehmen liegen uns keine Analysten-Daten vor.


Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.


  • Foto von Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23
    21.03. - 07:01 Uhr

    Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23

    BERKELEY, Calif. and MAINZ, Germany, March 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced that Bill Caragol, the Company's CFO, will present and host one-on-one meetings with investors at the Sidoti March Virtual Investor Conference, taking place on March 22-23, 2023. The presentation will begin at 12:15 ET on March 22, 2023 and can be accessed live here: Mainz Biomed will also host virtual one-on-ones with investors on Wednesday and Thursday, March 22-23, 2023. To register for the presentation or one-on-ones, visit Registration is free and you don't need to be a Sidoti client. About Sidoti & Company For over two decades, Sidoti & Company ( has been a premier provider of independent securities research focused specifically on small and microcap companies and the institutions that invest in their securities, with most of its coverage in the $100 million-$5 billion market cap range. The firm's approach affords companies and institutional clients a combination of high-quality research, a small- and microcap-focused nationwide sales effort, broad access to corporate management teams, and extensive trading support. Sidoti serves 500+ institutional clients in North America. About ColoAlert ColoAlert, Mainz Biomed's flagship product, delivers high sensitivity and specificity in a user-friendly, at-home colorectal cancer (CRC) screening kit. This non-invasive test can be indicative of tumors as determined by analyzing tumor DNA, offering better early detection than fecal occult blood tests (FOBT). Based on PCR-technology, ColoAlert detects more cases of colorectal cancer than other stool tests and allows for an earlier diagnosis (Gies et al., 2018). The product is commercially available in select EU countries through a network of leading independent laboratories, corporate health programs, and via direct sales. To receive marketing approval in the US, ColoAlert will be evaluated in the FDA-registration trial ‘ReconAAsense'. Once approved in the US, the Company's commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.  About Colorectal Cancer Colorectal cancer (CRC) is the third most common cancer globally, with more than 1.9 million new cases reported in 2020, according to World Cancer Research Fund International. The US Preventive Services Task Force recommends that screening with stool DNA tests such as ColoAlert should be conducted once every three years starting at age 45. Each year in the US, 16.6 million colonoscopies are performed. However, roughly one-third of US residents aged 50-75 have never been screened for colon cancer. This gap in screening represents a $4.0B+ total market opportunity in the US.  About Mainz Biomed NV Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert is currently marketed across Europe. The Company is running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed's product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit or follow us on LinkedIn , Twitter and Facebook .   For media inquiries, please contact » Mehr auf

  • Foto von Mainz Biomed: A Long-Term Bet Relying On Expanded Testing
    30.10. - 06:16 Uhr

    Mainz Biomed: A Long-Term Bet Relying On Expanded Testing

    Mainz Biomed is a German developer of genetic tests for various diseases, primarily cancer. At the moment, the company has one main product, ColoAlert, a colorectal cancer test that is so far only approved in some non-US countries. » Mehr auf

  • Foto von Mainz Biomed to Present at the H.C. Wainwright Annual Global Investment Conference
    01.09. - 07:01 Uhr

    Mainz Biomed to Present at the H.C. Wainwright Annual Global Investment Conference

    BERKELEY, Calif. and MAINZ, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Bill Caragol, Chief Financial Officer, will present at the H.C. Wainwright Annual Global Investment Conference taking place from September 12-14, 2022. » Mehr auf


Im letzten Quartal hatte Mainz Biomed B.V. einen Umsatz von 126,93k und ein Nettoeinkommen von 2,57 Mio
(EUR) Dez. 2021
Umsatz 126,93k -
Bruttoeinkommen 39,05k -
Nettoeinkommen 2,57 Mio -
EBITDA 2,49 Mio -


Metrik Wert
82,40 Mio
Anzahl Aktien
14,49 Mio
52 Wochen-Hoch/Tief
14,61 - 4,97
Dividenden Nein
KGV (PE Ratio)
KGWV (PEG Ratio)
KBV (PB Ratio)
KUV (PS Ratio)


Mainz Biomed B.V., ein molekulargenetisches Krebsdiagnoseunternehmen, entwickelt In-vitro-Diagnosetests (IVD) und reine Forschungstests für die klinische Diagnostik in der Humangenetik. Das Unternehmen bietet ColoAlert, einen Screening-Test für Darmkrebs, PancAlert, einen Produktkandidaten für einen Screening-Test für Bauchspeicheldrüsenkrebs, GenoStrip zum Nachweis von Krankheitserregern in der Umwelt auf molekulargenetischer Basis sowie IVD-Tests für Forschungszwecke an. Das Unternehmen wurde 2008 gegründet und hat seinen Sitz in Mainz, Deutschland.

Mainz Biomed B.V.
Mr. Guido Baechler
Sitz Mainz,
Mitarbeiter 0

Ticker Symbole

Börse Symbol

Wir arbeiten hart, um Hürden für den Vermögensaufbau zu senken. Für alle.

Parqet im Apple App Store Parqet im Google Play Store

Daten Disclaimer

Parqet Fintech GmbH übernimmt für die dargestellten Informationen und deren Genauigkeit und Vollständigkeit keine Gewährleistung.

Quellen für Kurse sind Gettex, Lang & Schwarz und weitere Handelsplätze sowie AG, ActivFinancial, EDI und QuoteMedia.

Quelle für Fundamentaldaten sind die Firmenunterlagen der jeweiligen Unternehmen. Quelle für ETF-Daten sind die Webseiten und Datenblätter der jeweiligen ETF-Anbieter. Dividenden-Daten überwiegend von DivvyDiary.

Fehler gefunden? Bitte sende Feedback zu den dargestellten Daten an

Manche Logos werden von Clearbit bereit gestellt.

Link Disclaimer

Für manche Links kann Parqet Fintech GmbH eine Affiliate-Provision erhalten wenn Produkte darüber erworben werden. Dies hilft dabei, kostenlose Produkte und Inhalte auf Parqet zu finanzieren.

© 2023 Parqet


Parqet nutzt Cookies. Erfahre Mehr